Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 112-115 , 25 January 2010

Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: Proteomic analysis

  • Setsu Sawai

      Affiliations

    • Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 43 222 7171x5450; fax: +81 43 226 2169.
    • ,
  • Hiroshi Umemura

      Affiliations

    • Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
    • ,
  • Masahiro Mori

      Affiliations

    • Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Mamoru Satoh

      Affiliations

    • Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
    • ,
  • Sei Hayakawa

      Affiliations

    • Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Yoshio Kodera

      Affiliations

    • Department of Physics, School of Science, Kitasato University, Kanagawa, Japan
    • ,
  • Takeshi Tomonaga

      Affiliations

    • Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
    • ,
  • Satoshi Kuwabara

      Affiliations

    • Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan
    • ,
  • Fumio Nomura

      Affiliations

    • Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

Received 3 July 2009 ,Revised 22 October 2009 ,Accepted 23 October 2009.

References 

  1. Aranami T, Miyake S, Yamamura T. Differential expression of CD11c by peripheral blood NK cells reflects temporal activity of multiple sclerosis. J. Immunol. 2006;177:5659–5667
  2. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691–1695
  3. Del Boccio P, Pieragostino D, Lugaresi A, Di Ioia M, Pavone B, Travaglini D, et al. Cleavage of cystatin C is not associated with multiple sclerosis. Ann. Neurol. 2007;62:201–204
  4. Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J. Proteome Res. 2006;5:2152–2158
  5. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet. Neurol. 2008;7:852–858
  6. Frisullo G, Angelucci F, Caggiula M, Nociti V, Iorio R, Patanella AK, et al. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing–remitting multiple sclerosis patients correlates with disease activity. J. Neurosci. Res. 2006;84:1027–1036
  7. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 2006;63:614–619
  8. Goldman R, Ressom HW, Abdel-Hamid M, Goldman L, Wang A, Varghese RS, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007;28:2149–2153
  9. International Multiple Sclerosis Genetics Consortium, Hafler, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J., De Jager, P.L., de Bakker, P.I., Gabriel, S.B., Mirel, D.B., Ivinson, A.J., Pericak-Vance, M.A., Gregory, S.G., Rioux, J.D., McCauley, J.L., Haines, J.L., Barcellos, L.F., Cree, B., Oksenberg, J.R., Hauser, S.L., 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851–862.
  10. Irani DN, Anderson C, Gundry R, Cotter R, Moore S, Kerr DA, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 2006;59:237–247
  11. Jans H, Heltberg A, Zeeberg I, Kristensen JH, Fog T, Raun NE. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta. Neurol. Scand. 1984;69:34–38
  12. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing–remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2006;77:185–188
  13. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006;355:124–140
  14. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet. Neurol. 2007;6:431–441
  15. Koning N, Bo L, Hoek RM, Huitinga I. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann. Neurol. 2007;62:504–514
  16. Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer F, et al. Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing–remitting disease course of multiple sclerosis. J. Neuroimmunol. 2005;167:143–149
  17. Mahad DJ, Lawry J, Howell SJ, Woodroofe MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult. Scler. 2003;9:189–198
  18. Onodera H, Nakashima I, Fujihara K, Nagata T, Itoyama Y. Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing–remitting multiple sclerosis. Tohoku. J. Exp. Med. 1999;189:259–265
  19. Pittock SJ, Weinshenker BG, Noseworthy JH, Lucchinetti CF, Keegan M, Wingerchuk DM, et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 2006;63:611–614
  20. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 2005;58:840–846
  21. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006;354:899–910
  22. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 2006;354:911–923
  23. Steiner I, Nisipianu P, Wirguin I. Infection and the etiology and pathogenesis of multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2001;1:271–276
  24. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol. 1998;43:465–471
  25. Umemura, H., Nezu, M., Kodera, Y., Satoh, M., Kimura, A., Tomonaga, T., Nomura, F., 2009. Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta 406, 179-180.
  26. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006;116:271–284
  27. Zhang X, Leung SM, Morris CR, Shigenaga MK. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J. Biomol. Tech. 2004;15:167–175

PII: S0165-5728(09)00434-2

doi: 10.1016/j.jneuroim.2009.10.019

Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 112-115 , 25 January 2010

Article Tools

* Image Usage & Resolution